Publication | Open Access

Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Rheumatoid DisorderRheumatologyYears Drug SurvivalSpondyloarthritisMedicineRheumatic DiseasesPharmacologyInflammatory Rheumatic DiseaseClinical OutcomesPharmacotherapyPsoriatic ArthritisInflammatory ArthritisRheumatoid Arthritis